Why these ASX firms are shying away from the 'pot stock' label – Part 2 theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.
ASX cannabis stocks making almighty push for approval with clinical trials theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.
Dr Boreham's Crucible: Arovella Therapeutics fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has launched a new clinical program into the use of daily oral cannabinoid-based drug to potentially treat Rett Syndrome in female patients.
Arovella Therapeutics Ltd (ASX:ALA) has welcomed medtech stalwart Dr Thomas Duthy as its next non-executive chair. The incoming executive will take the.